Jyong Biotech Ltd. (MENS) intrinsic value & 10-year financials
Jyong Biotech Ltd. (MENS) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- 14.2%
- Free cash flow (FY2025)
- —
MENS 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$4.7M | -$0.06 | — | — | 20.7% |
| FY2024 | — | -$3.0M | -$0.04 | — | — | 8.2% |
| FY2023 | — | -$4.4M | -$0.06 | — | — | 13.8% |
| FY2022 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Jyong Biotech Ltd. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Jyong Biotech Ltd. returns on capital have been average, hovering around 14.2% ROIC over the decade.
Jyong Biotech Ltd. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Jyong Biotech Ltd. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.